Diferencia entre revisiones de «Octreotide»
Sin resumen de edición |
|||
| Línea 35: | Línea 35: | ||
A peptide that mimics endogenous somatostatin. Somatostatin is released by the pancreas, pyloric antrum, and duodenum and inhibits growth hormone, gastrin, Vasoactive intestinal peptide (VIP), gastrin, serotonin, and decreases Insulin like growth factor-1 (IGF-1) and decreases splanchnic blood flow. | A peptide that mimics endogenous somatostatin. Somatostatin is released by the pancreas, pyloric antrum, and duodenum and inhibits growth hormone, gastrin, Vasoactive intestinal peptide (VIP), gastrin, serotonin, and decreases Insulin like growth factor-1 (IGF-1) and decreases splanchnic blood flow. | ||
==Comments== | ==Comments== | ||
Although used in the ED mainly for sulfonylurea overdose and vatical bleeding, it is used in outpatient and inpatient medicine for the treatment of acromegaly, carcinoid tumors, and VIPomas | |||
==See Also== | ==See Also== | ||
Revisión del 21:03 11 may 2016
Administration
- Type: Octapeptide
- Dosage Forms:
- Routes of Administration: IV, IM
- Common Trade Names: Sandostatin, Sandostatin LAR
Adult Dosing
Pediatric Dosing
Special Populations
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
A peptide that mimics endogenous somatostatin. Somatostatin is released by the pancreas, pyloric antrum, and duodenum and inhibits growth hormone, gastrin, Vasoactive intestinal peptide (VIP), gastrin, serotonin, and decreases Insulin like growth factor-1 (IGF-1) and decreases splanchnic blood flow.
Comments
Although used in the ED mainly for sulfonylurea overdose and vatical bleeding, it is used in outpatient and inpatient medicine for the treatment of acromegaly, carcinoid tumors, and VIPomas